|Articles|April 1, 2014

Applied Clinical Trials-04-01-2014
Volume 23
Issue 4

Applied Clinical Trials Digital Edition April/May 2014

Sites: Making a Difference in Cancer Trials Accrual Trial Design: Oncology Trial Comparator Drug Reimbursement Also in this issue: Singular Approach to Combination Trials Risk Sharing and Interrupted Drug Development Cardio-Oncology: A New Clinical Discipline

External Link - 2014-04ACT.pdf

Articles in this issue

over 12 years ago

Article

Oncology Trial Comparator Drug Reimbursement: A Canadian Perspective

over 12 years ago

Article

Business and People April 2014

over 12 years ago

Article

Europe Puts Renewed Emphasis on Patient Communication

over 12 years ago

Article

Making a Difference in Cancer Trials Accrual

over 12 years ago

Article

Analyzing 2013 Oncology Trends to Predict 2014 Directions

over 12 years ago

Article

Singular Approaches to Combination Trials

over 12 years ago

Article

Delivery Strength from Midsize CROs

over 12 years ago

Article

Pressure Grows for More Inclusive Clinical Trials

over 12 years ago

Article

Coming to Terms with Interrupted Drug Development Programs

over 12 years ago

Article

The New Road of Cardio-Oncology in Clinical Development

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

September 18th, 2026

DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.

Scaling AI in life sciences takes more than more tools, it takes a platform that connects workflows, data and governance. Credit: Stock.Adobe.com/Grispb.

September 18th, 2026

How a Platform Approach Can Scale AI’s Impact in Life Sciences

A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.

September 18th, 2026

ACT Brief: Patient Voice as Methodology, AI System Bottlenecks, Regulatory Convergence on Patient Input

In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com

September 17th, 2026

What "Patient Voice" Actually Requires: Beyond the Buzzword

The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.

September 17th, 2026

Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities

Why clinical development’s next AI bottleneck is not the model, but the system around it.

September 17th, 2026

ACT Brief: Expedited IND Pilot Launch, Operating Model Importance, and Readiness Prediction

In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

September 16th, 2026

FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines

The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.

© FlowStudio - © FlowStudio - stock.adobe.com

September 16th, 2026

Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy

A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.

Applied Clinical Trials Digital Edition April/May 2014

Articles in this issue

Related to this article

Trending on Applied Clinical Trials Online

Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities

DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now

The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026

The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver

Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy